News

National Institute for Health and Care Excellence6h
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
30 November 2023 Please note that following on from advice received from the company this appraisal has been rescheduled. We now anticipate that the appraisal will begin during late-April 2024 when we ...
The National Institute for Health and Care Excellence4d
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...
The National Institute for Health and Care Excellence6d
New weekly treatment option approved for people with haemophilia B
Given as a once-weekly injection under the skin using a pre-filled syringe or pen, marstacimab is also the first haemophilia B treatment that works by targeting a protein in the blood clotting process ...
The National Institute for Health and Care Excellence13d
Deal agreed for continued access to life-changing treatment for rare inherited disease
NICE, together with NHS England, remains committed to working with the company to try to reach a long-term deal that will give access to cerliponase alfa to all eligible people after that time.
The National Institute for Health and Care Excellence13d
Health inequalities - an update to NICE’s methods for health technology evaluation
This month we published a modular update to our health technology evaluations manual focusing on how we consider the effect of health technologies on health inequalities. The update is designed to ...
National Institute for Health and Care Excellence16d
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
There is a simple discount patient access scheme for erdafitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence16d
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...
National Institute for Health and Care Excellence16d
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...
National Institute for Health and Care Excellence18d
Technology for children and young people with chronic tic disorders and Tourette syndrome recommended
A digital therapy that could reduce the severity of the symptoms of chronic tic disorders and Tourette syndrome has been conditionally recommended for NHS use. For the first time, a NICE committee has ...
National Institute for Health and Care Excellence20d
Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management
You can now comment on this draft scope. The scope defines what the guideline will (and will not) cover. NICE is transforming to deliver more timely, relevant and impactful guidance while maintaining ...
National Institute for Health and Care Excellence20d
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...